相关实验视频

Updated: Jul 6, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

乳糖和益生菌的同时使用改善了小鼠的洛佩拉胺诱导的便秘

Chun Woong Park¹, Jihyun Lee¹, Yang Hee Hong²

¹Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul 02841, Korea.

Preventive nutrition and food science

|January 8, 2024

概括

乳酪糖与Bacillus licheniformis或Saccharomyces boulardii等益生菌相结合,通过改善便质量和肠道通道,有效缓解便秘. 这种组合增强了短链脂肪酸的产生,与单独的乳糖相比,提供了更好的治疗效果.

科学领域:

胃肠病学胃肠病学
微生物学微生物学
药理学药理学是指药理学的学科.

背景情况:

便秘是一种常见的胃肠道疾病,对生活质量产生重大影响.
洛佩拉胺诱导的便秘模型被广泛用于研究药作用.
益生菌和益生菌,如乳糖,显示在控制便秘的潜力.

研究的目的:

为了评估乳糖与特定益生菌菌株结合用于缓解便秘的疗效.
为了确定合适的益生菌菌株,以改善便秘,当与乳糖一起使用时.
为了比较乳糖-益生菌混合物与乳糖-氧化的作用.

主要方法:

在使用洛佩拉米德的雄性ICR小鼠中诱导便秘.
通过分析便参数,胃肠道过渡率和便短链脂肪酸 (SCFA) 含量来评估便作用.
小鼠接受了单独的乳糖治疗,乳糖使用Bacillus licheniformis,乳糖使用Saccharomyces boulardii,或乳糖使用氧化.

主要成果:

与洛佩拉胺诱导的便秘相比,与B. licheniformis或S. boulardii一起的乳糖显著改善了便数量和水含量.
联合使用增加了胃肠道过渡率和SCFA总含量,包括酸盐.
乳酪糖-氧化还改善了便参数和胃肠道过渡,并增加了SCFA含量.

结论:

乳糖与益生菌 (B. licheniformis或S. boulardii) 的联合治疗有效缓解便秘症状.
该机制涉及增加便中的SCFA含量,这表明肠道微生物群调节具有有益作用.
乳酪糖-益生菌混合物在这个模型中显示出比单独的乳酪糖更高的疗效.

关键词:

细菌类类类这种植物是Saccharomyces boulardii.便秘便秘便秘便秘乳糖糖是什么乳糖是什么乳糖是什么氧化是什么? 氧化是什么?

更多相关视频

Probiotic Studies in Neonatal Mice Using Gavage

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

相关概念视频

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs Affecting GI Tract Motility: Other Laxatives

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...